Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.18.7849

Effect of Trichostatin A on Anti HepG2 Liver Carcinoma Cells: Inhibition of HDAC Activity and Activation of Wnt/β-Catenin Signaling  

Shi, Qing-Qiang (Laboratory of Stem Cell and Tissue Engineering, Department of Histology and Embryology, Chongqing Medical University)
Zuo, Guo-Wei (Laboratory of Clinical Diagnostics, Chongqing Medical University)
Feng, Zi-Qiang (Laboratory of Stem Cell and Tissue Engineering, Department of Histology and Embryology, Chongqing Medical University)
Zhao, Lv-Cui (Laboratory of Stem Cell and Tissue Engineering, Department of Histology and Embryology, Chongqing Medical University)
Luo, Lian (Laboratory of Stem Cell and Tissue Engineering, Department of Histology and Embryology, Chongqing Medical University)
You, Zhi-Mei (Laboratory of Stem Cell and Tissue Engineering, Department of Histology and Embryology, Chongqing Medical University)
Li, Dang-Yang (Laboratory of Stem Cell and Tissue Engineering, Department of Histology and Embryology, Chongqing Medical University)
Xia, Jing (Laboratory of Stem Cell and Tissue Engineering, Department of Histology and Embryology, Chongqing Medical University)
Li, Jing (Laboratory of Stem Cell and Tissue Engineering, Department of Histology and Embryology, Chongqing Medical University)
Chen, Di-Long (Laboratory of Stem Cell and Tissue Engineering, Department of Histology and Embryology, Chongqing Medical University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.18, 2014 , pp. 7849-7855 More about this Journal
Abstract
Purpose: To investigate the effect of deacetylase inhibitory trichostatin A (TSA) on anti HepG2 liver carcinoma cells and explore the underlying mechanisms. Materials and Methods: HepG2 cells exposed to different concentrations of TSA for 24, 48, or 72h were examined for cell growth inhibition using CCK8, changes in cell cycle distribution with flow cytometry, cell apoptosis with annexin V-FTIC/PI double staining, and cell morphology changes under an inverted microscope. Expression of ${\beta}$-catenin, HDAC1, HDAC3, H3K9, CyclinD1 and Bax proteins was tested by Western blotting. Gene expression for ${\beta}$-catenin, HDAC1and HDAC3 was tested by q-PCR. ${\beta}$-catenin and H3K9 proteins were also tested by immunofluorescence. Activity of Renilla luciferase (pTCF/LEF-luc) was assessed using the Luciferase Reporter Assay system reagent. The activity of total HDACs was detected with a HDACs colorimetric kit. Results: Exposure to TSA caused significant dose-and time-dependent inhibition of HepG2 cell proliferation (p<0.05) and resulted in increased cell percentages in G0/G1 and G2/M phases and decrease in the S phase. The apoptotic index in the control group was $6.22{\pm}0.25%$, which increased to $7.17{\pm}0.20%$ and $18.1{\pm}0.42%$ in the treatment group. Exposure to 250 and 500nmol/L TSA also caused cell morphology changes with numerous floating cells. Expression of ${\beta}$-catenin, H3K9and Bax proteins was significantly increased, expression levels of CyclinD1, HDAC1, HDAC3 were decreased. Expression of ${\beta}$-catenin at the genetic level was significantly increased, with no significant difference in HDAC1and HDAC3 genes. In the cytoplasm, expression of ${\beta}$-catenin fluorescence protein was not obvious changed and in the nucleus, small amounts of green fluorescence were observed. H3K9 fluorescence protein were increased. Expression levels of the transcription factor TCF werealso increased in HepG2 cells following induction by TSA, whikle the activity of total HDACs was decreased. Conclusions: TSA inhibits HDAC activity, promotes histone acetylation, and activates Wnt/${\beta}$-catenin signaling to inhibit proliferation of HepG2 cell, arrest cell cycling and induce apoptosis.
Keywords
HepG2 cells; TSA; apoptosis; HDAC; ${\beta}$-catenin; histone acetylation;
Citations & Related Records
Times Cited By KSCI : 4  (Citation Analysis)
연도 인용수 순위
1 Bai L, Merchant JL (2007). A role for CITED2, a CBP/p300 interacting protein, in colon cancer cell invasion. FEBS Letters, 581, 5904-10.   DOI   ScienceOn
2 Barbetti V, Gozzini A, Cheloni G, et al (2013). Time- and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO-positive leukemia cells. Epigenetics, 8, 210-9.   DOI
3 Chen W-Q, Xu B, Mao J-W, et al (2014). Inhibitory effects of $\alpha$-pinene on hepatoma carcinoma cell proliferation. Asian Pac J Cancer Prev, 15, 3293-7.   과학기술학회마을   DOI   ScienceOn
4 Cui J, Zhou X, Liu Y, et al (2001). Mutation and overexpression of the $\beta$-catenin gene may play an important role in primary hepatocellular carcinoma among Chinese people. J Cancer Res Clin Oncol, 127, 577-81.   DOI   ScienceOn
5 Dahmani R, Just PA, Perret C (2011). The Wnt/$\beta$-catenin pathway as a therapeutic target in human hepatocellular carcinoma. Clin Res Hepatol Gastroenterol, 35, 709-13.   DOI
6 Debeb BG, Lacerda L, Xu W, et al (2012). Histone deacetylase inhibitors stimulate dedifferentiation of human breast cancer cells through WNT/$\beta$-catenin signaling. Stem Cells, 30, 2366-77.   DOI
7 Herold C, Ganslmayer M, Ocker M, et al (2002). The histonedeacetylase inhibitor Trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells. J Hepatol, 36, 233-40.
8 Feng D, Wu J, Tian Y, et al (2013). Targeting of histone deacetylases to reactivate tumour suppressor genes and its therapeutic potential in a human cervical cancer xenograft model. PLoS One, 8, 80657-68.   DOI
9 Fujisawa K, Maesawa C, Sato R, et al (2005). Epigenetic status and aberrant expression of the maspin gene in human hepatobiliary tract carcinomas. Lab Invest, 85, 214-24.   DOI   ScienceOn
10 Haghshenas MR, Arabi M, Mousavi T (2014). Hepatitis B genotypes in iran. Mater Sociomed, 26, 129-33.   DOI   ScienceOn
11 Iguchi H, Urashima Y, Inagaki Y, et al (2007). SOX6 suppresses cyclin D1 promoter activity by interacting with $\beta$-catenin and histone deacetylase 1, and its down-regulation induces pancreatic $\beta$-cell proliferation. J Biol Chem, 282, 19052-61.   DOI   ScienceOn
12 Ji Z, Wang T, Shao Z, et al (2014). A population-based study examining hepatitis B virus infection and immunization rates in Northwest China. PLoS One, 9, 97474-84.   DOI   ScienceOn
13 Ker CG, Chen JS, Kuo KK, et al (2011). Liver surgery for hepatocellular carcinoma: laparoscopic versus open approach. Int J Hepatol, 2011, 596792.
14 Lazarova DL, Bordonaro M, Carbone R, et al (2004). Linear relationship between Wnt activity levels and apoptosis in colorectal carcinoma cells exposed to butyrate. Int J Cancer, 110, 523-31.   DOI   ScienceOn
15 Lee JE, Bae SH, Choi JY, et al (2014). Epirubicin, cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma. World J Gastroenterol, 20, 235-41.   DOI   ScienceOn
16 Miyoshi H, Deguchi A, Nakau M, et al (2009). Hepatocellular carcinoma development induced by conditional $\beta$-catenin activation in Lkb1+/- mice. Cancer Sci, 100, 2046-53.   DOI   ScienceOn
17 Mosimann C, Hausmann G, Basler K (2009). Beta-catenin hits chromatin: regulation of Wnt target gene activation. Nat Rev Mol Cell Biol, 10, 276-86.   DOI   ScienceOn
18 Li J-P, Cao N-X, Jiang R-T, et al (2014). Knockdown of GCF2/LRRFIP1 by RNAi causes cell growth inhibition and increased apoptosis in human hepatoma HepG2 cells. Asian Pac J Cancer Prev, 15, 2753-8.   과학기술학회마을   DOI   ScienceOn
19 Marks P, Rifkind RA, Richon VM, et al (2001). Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer, 1, 194-202.   DOI   ScienceOn
20 Miyahara K, Nouso K, Yamamoto K (2014). Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age. World J Gastroenterol, 20, 4151-9.   DOI   ScienceOn
21 Myzak MC, Karplus PA, Chung FL, et al (2004). A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase. Cancer Res, 64, 5767-74.   DOI   ScienceOn
22 Osaki A, Suda T, Kamimura K, et al (2013). A safe and effective dose of cisplatin in hepatic arterial infusion chemotherapy for hepatocellular carcinoma. Cancer Med, 2, 86-98.   DOI
23 Page AJ, Cosgrove DC, Philosophe B, et al (2014). Hepatocellular carcinoma: diagnosis, management, and prognosis. Surg Oncol Clin N Am, 23, 289-311.   DOI   ScienceOn
24 Pathil A, Armeanu S, Venturelli S, et al (2006). HDAC inhibitor treatment of hepatoma cells induces both TRAILindependent apoptosis and restoration of sensitivity to TRAIL. Hepatology, 43, 425-34.   DOI   ScienceOn
25 Quint K, Agaimy A, Di Fazio P, et al (2011). Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC. Virchows Arch, 459, 129-39.   DOI   ScienceOn
26 Tanase A-M, Dumitrascu T, Dima S, et al (2014). Influence of hepatitis viruses on clinico-pathological profiles and long-term outcome in patients undergoing surgery for hepatocellular carcinoma. Hepatobiliary Pancreatic Dis Int, 13, 162-72.   DOI
27 Thompson MD, Monga SP (2007). WNT/$\beta$-catenin signaling in liver health and disease. Hepatology, 45, 1298-305.   DOI   ScienceOn
28 Scaggiante B, Kazemi M, Pozzato G, et al (2014). Novel hepatocellular carcinoma molecules with prognostic and therapeutic potentials. World J Gastroenterol, 20, 1268-88.   DOI   ScienceOn
29 Shao N, Zou J, Li J, et al (2012). Hyper-activation of WNT/$\beta$-catenin signaling pathway mediates anti-tumor effects of histone deacetylase inhibitors in acute T lymphoblastic leukemia. Leuk Lymphoma, 53, 1769-78.   DOI   ScienceOn
30 Song W-F, Wang L, Huang W-Y, et al (2013). MiR-21 upregulation induced by promoter zone histone acetylation is associated with chemoresistance to gemcitabine and enhanced malignancy of pancreatic cancer cells. Asian Pac J Cancer Prev, 14, 7529-36.   과학기술학회마을   DOI   ScienceOn
31 Tsai WL, Lai KH, Liang HL, et al (2014). Hepatic arterial infusion chemotherapy for patients with huge unresectable hepatocellular carcinoma. PLoS One, 9, 92784.   DOI   ScienceOn
32 Venturelli S, Armeanu S, Pathil A, et al (2007). Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma. Cancer, 109, 2132-41.   DOI   ScienceOn
33 Wiltse J (2005). Mode of Action: Inhibition of histone deacetylase, altering WNT-dependent gene expression, and regulation of beta-catenin-developmental effects of valproic acid. Crit Rev Toxicol, 35, 727-38.   DOI   ScienceOn
34 Woo HJ, Lee SJ, Choi BT, et al (2007). Induction of apoptosis and inhibition of telomerase activity by trichostatin A, a histone deacetylase inhibitor, in human leukemic U937 cells. Exp Mol Pathol, 82, 77-84.   DOI   ScienceOn
35 Ying Y, Tao Q (2009). Epigenetic disruption of the WNT/$\beta$-catenin signaling pathway in human cancers. Epigenetics, 4, 307-12.   DOI
36 Zhang Q-C, Jiang S-J, Zhang S, et al (2012). Histone deacetylase inhibitor trichostatin a enhances antitumor effects of docetaxel or erlotinib in A549 cell line. Asian Pac J Cancer Prev, 13, 3471-6.   과학기술학회마을   DOI   ScienceOn
37 Xu L-B (2010). Staging systems for predicting survival of patients with hepatocellular carcinoma after surgery. World Journal of Gastroenterology, 16, 5257.   DOI
38 Yang XJ, Seto E (2007). HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene, 26, 5310-8.   DOI   ScienceOn